For example, GATA3 and MDM2 were found to be synthetic lethal in ER+ BC (46), and MDM2 inhibitor milademetan was tested in a phase II clinical trial (DEMETER – NCT05932667) in combination with fulvestrant in patients with GATA3-mutant, ER+/HER2− A/MBC but it was terminated due to financial issues. Here, ERBB2 is linked to breast cancer.